Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine a systematic review and meta-analysis

JAMA Psychiatry

Volumn 74, Issue 5, 2017, Pages 511-519

  Ashok, Abhishekh H ^a,b,c   Mizuno, Yuya ^c,d   Volkow, Nora D ^e,f   Howes, Oliver D ^a,b,c  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; COCAINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; METHAMPHETAMINE; METHYLPHENIDATE; VESICULAR MONOAMINE TRANSPORTER; DOPAMINE RECEPTOR;

CASE CONTROL STUDY; DEMOGRAPHY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG WITHDRAWAL; EMBASE; HUMAN; IN VIVO STUDY; MEDLINE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PSYCINFO; REVIEW; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; AMPHETAMINE DEPENDENCE; COCAINE DEPENDENCE; CORPUS STRIATUM; META ANALYSIS; METABOLISM;

AMPHETAMINE-RELATED DISORDERS; COCAINE-RELATED DISORDERS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; RECEPTORS, DOPAMINE;

EID: 85018763138     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2017.0135     Document Type: Review

References (105)

1. United Nations Office on Drugs and Crime. World Drug Report 2015. http://www.unodc.org/wdr2015/. Accessed February 6, 2017.
2. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55-70.
3. Di Chiara G, Bassareo V. Reward system and addiction: what dopamine does and doesn'tdo. Curr Opin Pharmacol. 2007;7(1):69-76.
4. Keiflin R, Janak PH. Dopamine prediction errors in reward learning and addiction: from theory to neural circuitry. Neuron. 2015;88(2):247-263.
5. Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR. The dopamine theoryof addiction: 40 years of highs and lows. Nat Rev Neurosci. 2015;16 (5):305-312.
6. Volkow ND, Morales M. The brain ondrugs: from reward to addiction. Cell. 2015;162(4):712-725.
7. Willuhn I, Burgeno LM, Groblewski PA, Phillips PE. Excessive cocaine use results from decreased phasic dopamine signaling in the striatum. Nat Neurosci. 2014;17(5):704-709.
8. Calipari ES, Ferris MJ. Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci. 2013;33(21):8923-8925.
9. Daberkow DP, Brown HD, Bunner KD, et al. Amphetamine paradoxically augments exocytotic dopamine release and phasic dopamine signals. J Neurosci. 2013;33(2):452-463.
10. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681-698.
11. Kahlig KM, Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol. 2003;479(1-3):153-158.
12. Willuhn I, Wanat MJ, Clark JJ, Phillips PE. Dopamine signaling inthe nucleus accumbens of animals self-administering drugs of abuse. Curr Top Behav Neurosci. 2010;3:29-71.
13. Kim E, Howes OD, Kapur S. Molecular imaging as a guide for the treatment of central nervous system disorders. Dialogues Clin Neurosci. 2013;15 (3):315-328.
14. Laruelle M, Abi-Dargham A, van Dyck CH, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995;36(7): 1182-1190.
15. 2 receptors. J Pharmacol Exp Ther. 1999;291(1):409-415.
16. Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage. 2010;50(2):524-531.
17. Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature. 1997;386(6627):830-833.
18. Volkow ND, Wang GJ, Ma Y, et al. Activation of orbital and medial prefrontal cortex by methylphenidate in cocaine-addicted subjects but not in controls: relevance to addiction. J Neurosci. 2005;25(15):3932-3939.
19. Martinez D, Narendran R, Foltin RW, et al. Amphetamine-induced dopamine release: markedly bluntedin cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry. 2007;164(4):622-629.
20. Martinez D, Carpenter KM, Liu F, et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry. 2011;168(6):634-641.
21. Schrantee A, Václavu L, Heijtel DF, et al. Dopaminergic system dysfunction in recreational dexamphetamine users. Neuropsychopharmacology. 2015;40(5):1172-1180.
22. Wang GJ, Smith L, Volkow ND, et al. Decreased dopamine activity predicts relapse in methamphet-amine abusers. Mol Psychiatry. 2012;17(9):918-925.
23. Volkow ND, Tomasi D, Wang GJ, et al. Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers. Mol Psychiatry. 2014;19(9):1037-1043.
24. Crits-Christoph P, Newberg A, Wintering N, et al. Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend. 2008; 98(1-2):70-76.
25. 123I]β-CIT SPECT. Am J Psychiatry. 1998;155(6):832-834.
26. Wang GJ, Volkow ND, Fowler JS, et al. Cocaine abusersdonot show loss of dopamine transporters with age. Life Sci. 1997;61(11):1059-1065.
27. Chou YH, Huang WS, Su TP, Lu RB, Wan FJ, Fu YK. Dopamine transporters and cognitive function inmethamphetamine abuser after a short abstinence: A SPECT study. Eur Neuropsychopharmacol. 2007;17(1):46-52.
28. Johanson CE, Frey KA, Lundahl LH, et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl). 2006;185(3): 327-338.
29. McCann UD, Kuwabara H, Kumar A, et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse. 2008;62(2):91-100.
30. 11C]WIN-35, 428. J Neurosci. 1998;18 (20):8417-8422.
31. Schouw ML, Caan MW, Geurts HM, et al. Monoaminergic dysfunction in recreational users of dexamphetamine. Eur Neuropsychopharmacol. 2013;23(11):1491-1502.
32. Sekine Y, Iyo M, Ouchi Y, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001;158(8):1206-1214.
33. Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21(23):9414-9418.
34. Yuan J, Lv R, Robert Braic J, et al. Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence. Psychiatry Res. 2014;221(1): 92-96.
35. Volkow ND, Wang GJ, Smith L, et al. Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release. Neuroimage. 2015;121:20-28.
36. Chang L, Wang GJ, Volkow ND, et al. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage. 2008;42(2):869-878.
37. Volkow ND, Wang GJ, Fowler JS, et al. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology. 1996; 14(3):159-168.
38. Okita K, Ghahremani DG, Payer DE, et al. Emotion dysregulation and amygdala dopamine D2-type receptor availability in methamphetamine users. Drug Alcohol Depend. 2016;161:163-170.
39. 3 receptor availability is associated with steep discounting of delayed rewards in methamphetamine dependence. Int J Neuropsychopharmacol. 2015;18(7):pyu119.
40. 11C]-(+)-PHNO inmethamphetamine polydrug users: a positron emission tomography study. J Neurosci. 2012;32(4):1353-1359.
41. 2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry. 2001;158(12):2015-2021.
42. Iyo M, Nishio M, Itoh T, et al. Dopamine D2 and serotonin S2 receptors in susceptibility to metham-phetamine psychosis detected by positron emission tomography. Psychiatry Res. 1993;50(4):217-231.
43. 3 receptors following acute dopamine depletion [published correction appears in Am J Psychiatry. 2009;166(11):1299]. Am J Psychiatry. 2009;166(10):1170-1177.
44. 11C](+)PHNO. Drug Alcohol Depend. 2014;139:100-105.
45. 11C]NPA PET study. Synapse. 2011;65(12):1344-1349.
46. Payer DE, Behzadi A, Kish SJ, et al. Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO. Neuropsychopharmacology. 2014;39(2):311-318.
47. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 1993;14(2):169-177.
48. Volkow ND, Fowler JS, Wolf AP, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry. 1990;147(6):719-724.
49. Wu JC, Bell K, Najafi A, et al. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology. 1997;17(6):402-409.
50. Narendran R, Lopresti BJ, Martinez D, et al. In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry. 2012;169(1):55-63.
51. Boileau I, Rusjan P, Houle S, et al. Increased vesicular monoamine transporter binding during early abstinence inhuman methamphetamine users: is VMAT2 astable dopamine neuron biomarker?JNeurosci. 2008;28(39):9850-9856.
52. Boileau I, McCluskey T, Tong J, Furukawa Y, Houle S, Kish SJ. Rapid recovery of vesicular dopamine levelsin methamphetamine users in early abstinence. Neuropsychopharmacology. 2016; 41(4):1179-1187.
53. Martinez D, Slifstein M, Narendran R, et al. Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine. Neuropsychopharmacology. 2009;34(7):1774-1782.
54. Volkow ND, Wang GJ, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386(6627):827-830.
55. Zahniser NR, Sorkin A. Rapid regulation of the dopamine transporter: role in stimulant addiction? Neuropharmacology. 2004;47(suppl 1):80-91.
56. Schmitt KC, Reith ME. Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Ann N Y Acad Sci. 2010;1187:316-340.
57. Han DD, Gu HH. Comparisonofthe monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006;6:6.
58. Egerton A, Mehta MA, Montgomery AJ, et al. The dopaminergic basisof human behaviors: a review of molecular imaging studies. Neurosci Biobehav Rev. 2009;33(7):1109-1132.
59. Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunctionin schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69(8):776-786.
60. 99mTc]-TRODAT-1 and a meta-analysis. Schizophr Bull. 2013;39(2):378-386.
61. Kambeitz J, Abi-Dargham A, Kapur S, Howes OD. Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry. 2014;204(6):420-429.
62. Selvaraj S, Arnone D, Cappai A, Howes O. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev. 2014;45:233-245.
63. Kambeitz JP, Howes OD. The serotonin transporter in depression: meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord. 2015;186:358-366.
64. Volkow ND, Wang GJ, Telang F, et al. Cocaine cues and dopaminein dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci. 2006;26 (24):6583-6588.
65. Wong DF, Kuwabara H, Schretlen DJ, et al. Increased occupancy ofdopamine receptors in human striatum during cue-elicited cocaine craving [published correction appears in Neuropsychopharmacology. 2007;32(1):256]. Neuropsychopharmacology. 2006;31(12):2716-2727.
66. Schiffer WK, Volkow ND, Fowler JS, Alexoff DL, Logan J, Dewey SL. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse. 2006;59(4):243-251.
67. Crippens D, Camp DM, Robinson TE. Basal extracellular dopamine in the nucleus accumbens during amphetamine withdrawal: a "no net flux" microdialysis study. Neurosci Lett. 1993;164(1-2):145-148.
68. Crippens D, Robinson TE. Withdrawal from morphine or amphetamine: different effects on dopamine in the ventral-medial striatum studied with microdialysis. Brain Res. 1994;650(1):56-62.
69. Paulson PE, Robinson TE. Regional differences in the effects of amphetamine withdrawal on dopa-mine dynamics in the striatum. Analysis of circadian patterns using automated on-line microdialysis. Neuropsychopharmacology. 1996;14(5):325-337.
70. Kuczenski R, Segal DS, Todd PK. Behavioral sensitization and extracellular dopamine responses to amphetamine after various treatments. Psychopharmacology (Berl). 1997;134(3):221-229.
71. Robinson TE, Jurson PA, Bennett JA, Bentgen KM. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) producedbyprior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res. 1988;462(2):211-222.
72. Segal DS, Kuczenski R. Repeated cocaine administration induces behavioral sensitization and corresponding decreased extracellular dopamine responsesin caudate and accumbens. Brain Res. 1992;577(2):351-355.
73. Hooks MS, Duffy P, Striplin C, Kalivas PW. Behavioral and neurochemical sensitization following cocaine self-administration. Psychopharmacology (Berl). 1994;115(1-2):265-272.
74. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine, I: dopamine axon terminals. J Neurosci. 1993;13(1):266-275.
75. Meil WM, Roll JM, Grimm JW, Lynch AM, See RE. Tolerance-like attenuation to contingent and noncontingent cocaine-induced elevation of extracellular dopamine in the ventral striatum following 7 days of withdrawal from chronic treatment [published correction appears in Psychopharmacology (Berl). 1995;121(2):285]. Psychopharmacology (Berl). 1995;118(3):338-346.
76. Heidbreder CA, Thompson AC, Shippenberg TS. Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine. J Pharmacol Exp Ther. 1996;278(2):490-502.
77. Imperato A, Mele A, Scrocco MG, Puglisi-Allegra S. Chronic cocaine alters limbic extracellular dopamine: neurochemical basis for addiction. Eur J Pharmacol. 1992;212(2-3):299-300.
78. Johnson DW, Glick SD. Dopamine release and metabolismin nucleus accumbens and striatum of morphine-tolerant and nontolerant rats. Pharmacol Biochem Behav. 1993;46(2):341-347.
79. Weiss F, Paulus MP, Lorang MT, Koob GF. Increases in extracellular dopamine in the nucleus accumbens by cocaine are inversely related to basal levels: effects of acute and repeated administration. J Neurosci. 1992;12(11):4372-4380.
80. Cunha-Oliveira T, Rego AC, Oliveira CR. Cellular and molecular mechanisms involved inthe neurotoxicity of opioid and psychostimulant drugs. Brain Res Rev. 2008;58(1):192-208.
81. LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci. 1999;19(4):1484-1491.
82. Tata DA, Yamamoto BK. Interactionsbetween methamphetamine and environmental stress: role of oxidative stress, glutamate and mitochondrial dysfunction. Addiction. 2007;102(suppl 1):49-60.
83. DeVito MJ, Wagner GC. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology. 1989;28(10):1145-1150.
84. Harvey DC, Lacan G, Tanious SP, Melega WP. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res. 2000; 871(2):259-270.
85. Melega WP, Jorgensen MJ, Lacan G, et al. Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles. Neuropsychopharmacology. 2008;33(6):1441-1452.
86. Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med. 1996;2(6):699-703.
87. Callaghan RC, Cunningham JK, Sykes J, Kish SJ. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamineorother amphetamine-type drugs. Drug Alcohol Depend. 2012;120(1-3):35-40.
88. Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR. Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. Drug Alcohol Depend. 2015;146:30-38.
89. Collier TJ, Kanaan NM, Kordower JH. Ageing as a primary risk factor for Parkinson's disease: evidence from studies ofnon-human primates. Nat Rev Neurosci. 2011;12(6):359-366.
90. Nestler EJ. Epigenetic mechanisms of drug addiction. Neuropharmacology. 2014;76(Pt B): 259-268.
91. Nestler EJ. Reflections on: "A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function." Brain Res. 2016;1645:71-74.
92. Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374(4):363-371.
93. Grace AA. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend. 1995;37(2):111-129.
94. 3H]spiperone. Mol Pharmacol. 2003;63(2):456-462.
95. Guo N, Guo W, Kralikova M, et al. Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers. Neuropsychopharmacology. 2010;35(3):806-817.
96. Volkow ND, Wang GJ, Tomasi D, et al. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvementin adults with attention deficit hyperactivity disorder. J Neurosci. 2012;32 (3):841-849.
97. Nader MA, Morgan D, Gage HD, et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci. 2006;9(8):1050-1056.
98. Caprioli D, Calu D, Shaham Y. Loss of phasic dopamine: a new addiction marker? Nat Neurosci. 2014;17(5):644-646.
99. Pérez-Mañá C, Castells X, Vidal X, Casas M, Capellà D. Efficacy of indirect dopamine agonists for psychostimulant dependence: a systematic review and meta-analysis of randomized controlled trials. J Subst Abuse Treat. 2011;40(2):109-122.
100. Thanos PK, Michaelides M, Umegaki H, Volkow ND. D2R DNA transfer into the nucleus accumbens attenuates cocaine self-administration in rats. Synapse. 2008;62(7):481-486.
101. Robertson CL, Ishibashi K, Chudzynski J, et al. Effect of exercise training on striatal dopamine D2/D3 receptorsin methamphetamine users during behavioral treatment. Neuropsychopharmacology. 2016;41(6):1629-1636.
102. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9(6):557-569.
103. Minozzi S, Amato L, Pani PP, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev. 2015;(5):CD003352.
104. Castells X, Cunill R, Pérez-Mañá C, Vidal X, Capellà D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016;9: CD007380.
105. Indave BI, Minozzi S, Pani PP, Amato L. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. 2016;3:CD006306.